London (PRWEB) October 14, 2013 <\/p>\n
Summary <\/p>\n
GlobalData has released its new Country report, PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action. <\/p>\n
GlobalData expects the PsO pipeline to begin launching hopefuls in 2015, starting with Novartis secukinumab and Celgenes apremilast. The following year, Mercks MK-3222, Lillys ixekizumab, Pfizers Xeljanz, and Amgens brodalumab will emerge, thus jamming the PsO market and making it difficult for each drug to gain market share. <\/p>\n
Scope <\/p>\n
-Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. -Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis. -Sales forecast for the top drugs in the UK from 2012 to 2022. -Analysis of the impact of key events as well the drivers and restraints affecting the UK Psoriasis market. <\/p>\n
Reasons to buy <\/p>\n
-Understand and capitalize by identifying products that are most likely to ensure a robust return -Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis -Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential -Make more informed business decisions from insightful and in-depth analysis of drug performance -Obtain sales forecast for drugs from 2012 to 2022 in the UK. 1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 9 2 Introduction 10 2.1 Catalyst 10 2.2 Related Reports 10 3 Disease Overview 13 3.1 Etiology and Pathophysiology 13 3.1.1 Etiology 13 3.1.2 Pathophysiology 15 3.2 Symptoms 18 4 Disease Management 19 4.1 Treatment Overview 20 4.2 UK 24 4.2.1 Diagnosis 24 4.2.2 Clinical Practice 24 5 Competitive Assessment 26 5.1 Overview 26 5.2 Strategic Competitor Assessment 27 5.3 Product Profiles Major Brands 28 5.3.1 Enbrel (etanercept) 28 5.3.2 Humira (adalimumab) 33 5.3.3 Remicade (infliximab) 38 5.3.4 Stelara (ustekinumab) 44 5.3.5 Taclonex (calcipotriene hydrate and betamethasone dipropionate) 49 5.3.6 Methotrexate Sodium (numerous generic names) 53 5.3.7 Minor Therapeutic Drug Classes Used in Psoriasis 57 5.3.8 Non-Pharmacological Therapy 58 6 Opportunity and Unmet Need 60 6.1 Overview 60 6.2 Unmet Needs 61 6.2.1 Improved Drug Safety and Efficacy Profiles 61 6.2.2 Biomarkers for Predicting Remission 62 6.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 62 6.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 63 6.2.5 An Effective Biologic\/Systemic Topical Therapy 63 6.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 64 6.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 64 6.3 Opportunities 65 6.4 Unmet Needs Gap Analysis 65 6.4.1 Predictive Tools for Diagnosis and Treatment 66 6.4.2 Target Specificity 66 6.4.3 Topical Biologic\/Systemic Therapeutic Options 67 6.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 67 7 Pipeline Assessment 68 7.1 Overview 68 7.2 Promising Drugs in Clinical Development 69 7.2.1 Brodalumab (AMG 827) 71 7.2.2 Secukinumab (AIN457) 77 7.2.3 Ixekizumab (LY2439821) 82 7.2.4 Tildrakizumab (MK-3222\/SCH-900222) 87 7.2.5 Xeljanz (tofacitinib) 91 7.2.6 Apremilast (CC-10004) 97 7.2.7 Phase II Pipeline Products 102 7.2.8 Phase I Pipeline Products 104 7.2.9 Biosimilars Pipeline Products 105 8 Market Outlook 108 8.1 United Kingdom 108 8.1.1 Forecast 108 8.1.2 Key Events 112 8.1.3 Drivers and Barriers 112 9 Appendix 115 9.1 Bibliography 115 9.2 Abbreviations 121 9.3 Methodology 125 9.4 Forecasting Methodology 125 9.4.1 Diagnosed Psoriasis Patients 125 9.4.2 Percent Drug-Treated Patients 126 9.4.3 Drugs Included in Each Therapeutic Class 126 9.4.4 Launch and Patent Expiry Dates 127 9.4.5 General Pricing Assumptions 128 9.4.6 Individual Drug Assumptions 129 9.4.7 Generic Erosion 133 9.4.8 Pricing of Pipeline agents 133 9.5 Physicians and Specialists Included in this Study 134 9.6 Primary Research Prescriber Survey 135 9.7 About the Authors 136 9.7.1 Analysts 136 9.7.2 Global Head of Healthcare 137 9.8 About GlobalData 138 9.9 Disclaimer 138 <\/p>\n
1.1 List of Tables <\/p>\n
Table 1: Immune Cells Involved in Lesions 15 Table 2: Symptoms of Psoriasis 18 Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis 21 Table 4: Treatment Guidelines for Psoriasis 23 Table 5: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2012 23 Table 6: Leading Treatments for Psoriasis, 2013 27 Table 7: Product Profile Enbrel 29 Table 8: Enbrel SWOT Analysis, 2013 32 Table 9: Product Profile Humira 34 Table 10: Humira SWOT Analysis, 2013 37 Table 11: Product Profile Remicade 39 Table 12: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26 40 Table 13: Safety Results (AEs) of RESTORE1 Trial of Remicade vs. MTX at Week 16 41 Table 14: Remicade SWOT Analysis, 2013 43 Table 15: Product Profile Stelara 45 Table 16: Stelara SWOT Analysis, 2013 48 Table 17: Product Profile Taclonex 50 Table 18: Taclonex SWOT Analysis, 2013 52 Table 19: Product Profile Methotrexate 54 Table 20: Methotrexate SWOT Analysis, 2013 56 Table 21: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2013 57 Table 22: Overall Unmet Needs in Psoriasis Current Level of Attainment 61 Table 23: Clinical Unmet Needs in Psoriasis Gap Analysis, 2013 66 Table 24: Psoriasis Phase Pipeline, 2013 69 Table 25: Comparison of Therapeutic Classes in Development for Psoriasis, 2013 70 Table 26: Product Profile Brodalumab 72 Table 27: Efficacy Results of Phase II Study of Brodalumab vs. Placebo at Week 12 73 Table 28: Brodalumab SWOT Analysis, 2013 76 Table 29: Product Profile Secukinumab 78 Table 30: Secukinumab SWOT Analysis, 2013 81 Table 31: Product Profile Ixekizumab 82 Table 32: Efficacy Results of Phase II Study of Ixekizumab vs. Placebo at Week 12 83 Table 33: Ixekizumab SWOT Analysis, 2013 86 Table 34: Product Profile Tildrakizumab 88 Table 35: Tildrakizumab SWOT Analysis, 2013 90 Table 36: Product Profile Xeljanz 92 Table 37: Xeljanz SWOT Analysis, 2013 96 Table 38: Product Profile Apremilast 98 Table 39: Efficacy Results of Phase IIb Study of Apremilast vs. Placebo at Week 16 99 Table 40: Apremilast SWOT Analysis, 2013 101 Table 41: Phase II Psoriasis Pipeline, 2013 102 Table 42: Phase I Psoriasis Pipeline, 2013 104 Table 43: Biosimilars Pipeline, 2013 107 Table 44: Sales Forecasts ($) for Psoriasis in the United Kingdom, 20122022 110 Table 45: Key Events Impacting Sales for Psoriasis in the United Kingdom, 20122022 112 Table 46: Psoriasis Market in the United Kingdom Drivers and Barriers, 20122022 112 Table 47: Key Launch Dates 127 Table 48: Key Patent Expiries 127 Table 49: Physicians Surveyed, By Country 135 <\/p>\n
<\/p>\n
Read the original post: London (PRWEB) October 14, 2013 Summary GlobalData has released its new Country report, PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. Continue reading
\nPharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"